NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
Updated: Feb 10
AMG 176
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia
Sponsor
ClinicalTrials.gov Identifier: NCT02675452
Official Title: A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
First Posted : February 5, 2016
Click here for details on ClinicalTrials.gov
MCL-1 Inhibitor AMG 176
Drug: AMG 176
Drug: Azacitidine
Drug: Itraconazole
Locations
United States, California
United States, Colorado
United States, Georgia
United States, Illinois
United States, Louisiana
United States, Massachusetts
United States, New Jersey
United States, Texas
United States, Utah
Australia, New South Wales
Australia, Victoria
Canada, Alberta
Canada, Ontario
Europe
Germany
Asia
Japan